A few recent Campaign updates from Treatment Action Group and allies.
Contact david.branigan@treatmentactiongroup.org for more information on how to be part of the 1/4/6x24 Campaign.

A report highlights that despite reaching US$1 billion in spending in 2021, funding for TB R&D is a mere fraction of what’s needed to achieve UN sustainable development goal of ending TB as a pandemic by 2030.

Statement by Treatment Action Group (TAG) and the Global Tuberculosis Community Advisory Board (TB CAB)

Materials designed to equip civil society and community-based organizations with the information they need to advocate for equitable access to the short-course treatment and prevention regimens at the heart of the 1/4/6×24 Campaign.

Treatment Action Group launches the 2022 Tuberculosis Diagnostics Pipeline Report.

Three storyboards describe the experiences of people who took TB preventive treatment (TPT): Daud Yamikani of Malawi took a three-month regimen called 3HP after his wife was treated for bone TB, Josephat Asande of Kenya took 3HP when his cousin was staying with him and undergoing treatment for drug-sensitive TB, and Ganesh Acharya of India took TPT for 36 months after a roommate developed TB back in 2009.

Treatment Action Group (TAG) launches the first TB chapter of its 2022 Pipeline Report.

Treatment Action Group (TAG) is seeking a dynamic, highly motivated, and organized Senior TB Project Associate to support community engagement activities under the SMART4TB Project – a $200 million investment made by USAID to Support, Mobilize, and Accelerate Research for TB Elimination.

At the International AIDS Conference in Montreal, civil society and activist organizations launched a new campaign inspired by the legacy of the late Dr. Paul Farmer calling for the “staff, stuff, space, systems, and support” necessary for shorter, effective TB treatment regimens to reach all who need them as a human right by the end of 2024.

In 2021, TB CAB celebrated its tenth anniversary of advocating for community engagement in research and improved access to TB prevention, treatment, and diagnostic technologies.